IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

Irini Sereti, Richard M. Dunham, John Spritzler, Evgenia Aga, Michael A. Proschan, Kathy Medvik, Catherine A. Battaglia, Alan L. Landay, Savita G Pahwa, Margaret A Fischl, David M. Asmuth, Allan R. Tenorio, John D. Altman, Lawrence Fox, Susan Moir, Angela Malaspina, Michel Morre, Renaud Buffet, Guido Silvestri, Michael M. Lederman

Research output: Contribution to journalArticle

230 Citations (Scopus)

Abstract

Interleukin 7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes. The safety and activity of recombinant human IL-7 (rhIL-7) administration were therefore examined in HIV-infected persons. In this prospective randomized placebo-controlled study, a single subcutaneous dose of rhIL-7 was well tolerated with biologic activity demonstrable at 3 μg/kg and a maximum tolerated dose of 30 μg/kg. Injection site reactions and transient elevations of liver function tests were the most notable side effects. Transient increases in plasma HIV-RNA levels were observed in 6 of 11 IL-7-treated patients. Recombinant hIL-7 induced CD4 and CD8 T cells to enter cell cycle; cell-cycle entry was also confirmed in antigen-specific CD8 T cells. Administration of rhIL-7 led to transient down-regulation of the IL-7 receptor alpha chain (CD127) in both CD4+ and CD8+ T cells. Single-dose rhIL-7 increased the numbers of circulating CD4+ and CD8+ T cells, predominantly of central memory phenotype. The frequency of CD4 + T cells with a regulatory T-cell phenotype (CD25high CD127low) did not change after rhIL-7 administration. Thus, rhIL-7 has a biologic and toxicity profile suggesting a potential for therapeutic trials in HIV infection and other settings of lymphopenia. This clinical trial has been registered at http:// www.clinicaltrials.gov under NCT0099671.

Original languageEnglish
Pages (from-to)6304-6314
Number of pages11
JournalBlood
Volume113
Issue number25
DOIs
StatePublished - Nov 19 2009

Fingerprint

Interleukin-7
T-cells
HIV Infections
HIV-1
Cell Cycle
T-Lymphocytes
Interleukin Receptor Common gamma Subunit
Cells
HIV
CD8 Antigens
Phenotype
Lymphopenia
Maximum Tolerated Dose
Liver Function Tests
Regulatory T-Lymphocytes
Human Activities
Liver
Toxicity
Down-Regulation
Placebos

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Sereti, I., Dunham, R. M., Spritzler, J., Aga, E., Proschan, M. A., Medvik, K., ... Lederman, M. M. (2009). IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood, 113(25), 6304-6314. https://doi.org/10.1182/blood-2008-10-186601

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. / Sereti, Irini; Dunham, Richard M.; Spritzler, John; Aga, Evgenia; Proschan, Michael A.; Medvik, Kathy; Battaglia, Catherine A.; Landay, Alan L.; Pahwa, Savita G; Fischl, Margaret A; Asmuth, David M.; Tenorio, Allan R.; Altman, John D.; Fox, Lawrence; Moir, Susan; Malaspina, Angela; Morre, Michel; Buffet, Renaud; Silvestri, Guido; Lederman, Michael M.

In: Blood, Vol. 113, No. 25, 19.11.2009, p. 6304-6314.

Research output: Contribution to journalArticle

Sereti, I, Dunham, RM, Spritzler, J, Aga, E, Proschan, MA, Medvik, K, Battaglia, CA, Landay, AL, Pahwa, SG, Fischl, MA, Asmuth, DM, Tenorio, AR, Altman, JD, Fox, L, Moir, S, Malaspina, A, Morre, M, Buffet, R, Silvestri, G & Lederman, MM 2009, 'IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection', Blood, vol. 113, no. 25, pp. 6304-6314. https://doi.org/10.1182/blood-2008-10-186601
Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009 Nov 19;113(25):6304-6314. https://doi.org/10.1182/blood-2008-10-186601
Sereti, Irini ; Dunham, Richard M. ; Spritzler, John ; Aga, Evgenia ; Proschan, Michael A. ; Medvik, Kathy ; Battaglia, Catherine A. ; Landay, Alan L. ; Pahwa, Savita G ; Fischl, Margaret A ; Asmuth, David M. ; Tenorio, Allan R. ; Altman, John D. ; Fox, Lawrence ; Moir, Susan ; Malaspina, Angela ; Morre, Michel ; Buffet, Renaud ; Silvestri, Guido ; Lederman, Michael M. / IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. In: Blood. 2009 ; Vol. 113, No. 25. pp. 6304-6314.
@article{d98b4a95c2074190919ff0e4893352c8,
title = "IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection",
abstract = "Interleukin 7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes. The safety and activity of recombinant human IL-7 (rhIL-7) administration were therefore examined in HIV-infected persons. In this prospective randomized placebo-controlled study, a single subcutaneous dose of rhIL-7 was well tolerated with biologic activity demonstrable at 3 μg/kg and a maximum tolerated dose of 30 μg/kg. Injection site reactions and transient elevations of liver function tests were the most notable side effects. Transient increases in plasma HIV-RNA levels were observed in 6 of 11 IL-7-treated patients. Recombinant hIL-7 induced CD4 and CD8 T cells to enter cell cycle; cell-cycle entry was also confirmed in antigen-specific CD8 T cells. Administration of rhIL-7 led to transient down-regulation of the IL-7 receptor alpha chain (CD127) in both CD4+ and CD8+ T cells. Single-dose rhIL-7 increased the numbers of circulating CD4+ and CD8+ T cells, predominantly of central memory phenotype. The frequency of CD4 + T cells with a regulatory T-cell phenotype (CD25high CD127low) did not change after rhIL-7 administration. Thus, rhIL-7 has a biologic and toxicity profile suggesting a potential for therapeutic trials in HIV infection and other settings of lymphopenia. This clinical trial has been registered at http:// www.clinicaltrials.gov under NCT0099671.",
author = "Irini Sereti and Dunham, {Richard M.} and John Spritzler and Evgenia Aga and Proschan, {Michael A.} and Kathy Medvik and Battaglia, {Catherine A.} and Landay, {Alan L.} and Pahwa, {Savita G} and Fischl, {Margaret A} and Asmuth, {David M.} and Tenorio, {Allan R.} and Altman, {John D.} and Lawrence Fox and Susan Moir and Angela Malaspina and Michel Morre and Renaud Buffet and Guido Silvestri and Lederman, {Michael M.}",
year = "2009",
month = "11",
day = "19",
doi = "10.1182/blood-2008-10-186601",
language = "English",
volume = "113",
pages = "6304--6314",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

AU - Sereti, Irini

AU - Dunham, Richard M.

AU - Spritzler, John

AU - Aga, Evgenia

AU - Proschan, Michael A.

AU - Medvik, Kathy

AU - Battaglia, Catherine A.

AU - Landay, Alan L.

AU - Pahwa, Savita G

AU - Fischl, Margaret A

AU - Asmuth, David M.

AU - Tenorio, Allan R.

AU - Altman, John D.

AU - Fox, Lawrence

AU - Moir, Susan

AU - Malaspina, Angela

AU - Morre, Michel

AU - Buffet, Renaud

AU - Silvestri, Guido

AU - Lederman, Michael M.

PY - 2009/11/19

Y1 - 2009/11/19

N2 - Interleukin 7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes. The safety and activity of recombinant human IL-7 (rhIL-7) administration were therefore examined in HIV-infected persons. In this prospective randomized placebo-controlled study, a single subcutaneous dose of rhIL-7 was well tolerated with biologic activity demonstrable at 3 μg/kg and a maximum tolerated dose of 30 μg/kg. Injection site reactions and transient elevations of liver function tests were the most notable side effects. Transient increases in plasma HIV-RNA levels were observed in 6 of 11 IL-7-treated patients. Recombinant hIL-7 induced CD4 and CD8 T cells to enter cell cycle; cell-cycle entry was also confirmed in antigen-specific CD8 T cells. Administration of rhIL-7 led to transient down-regulation of the IL-7 receptor alpha chain (CD127) in both CD4+ and CD8+ T cells. Single-dose rhIL-7 increased the numbers of circulating CD4+ and CD8+ T cells, predominantly of central memory phenotype. The frequency of CD4 + T cells with a regulatory T-cell phenotype (CD25high CD127low) did not change after rhIL-7 administration. Thus, rhIL-7 has a biologic and toxicity profile suggesting a potential for therapeutic trials in HIV infection and other settings of lymphopenia. This clinical trial has been registered at http:// www.clinicaltrials.gov under NCT0099671.

AB - Interleukin 7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes. The safety and activity of recombinant human IL-7 (rhIL-7) administration were therefore examined in HIV-infected persons. In this prospective randomized placebo-controlled study, a single subcutaneous dose of rhIL-7 was well tolerated with biologic activity demonstrable at 3 μg/kg and a maximum tolerated dose of 30 μg/kg. Injection site reactions and transient elevations of liver function tests were the most notable side effects. Transient increases in plasma HIV-RNA levels were observed in 6 of 11 IL-7-treated patients. Recombinant hIL-7 induced CD4 and CD8 T cells to enter cell cycle; cell-cycle entry was also confirmed in antigen-specific CD8 T cells. Administration of rhIL-7 led to transient down-regulation of the IL-7 receptor alpha chain (CD127) in both CD4+ and CD8+ T cells. Single-dose rhIL-7 increased the numbers of circulating CD4+ and CD8+ T cells, predominantly of central memory phenotype. The frequency of CD4 + T cells with a regulatory T-cell phenotype (CD25high CD127low) did not change after rhIL-7 administration. Thus, rhIL-7 has a biologic and toxicity profile suggesting a potential for therapeutic trials in HIV infection and other settings of lymphopenia. This clinical trial has been registered at http:// www.clinicaltrials.gov under NCT0099671.

UR - http://www.scopus.com/inward/record.url?scp=67650590873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650590873&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-10-186601

DO - 10.1182/blood-2008-10-186601

M3 - Article

C2 - 19380868

AN - SCOPUS:67650590873

VL - 113

SP - 6304

EP - 6314

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -